Agoracom Blog Home

Archive for the ‘Supreme Pharmaceuticals Inc’ Category

Supreme Obtains MMPR License to Cultivate Medical Marijuana

Posted by AGORACOM-JC at 3:37 PM on Friday, March 11th, 2016

Sllarge

  • Announce its wholly-owned subsidiary, Advanced Medical Marihuana Canada (“AMMCan”) has been granted a license to cultivate medical marijuana pursuant to the Marihuana for Medical Purposes Regulations (the “MMPR”)

TORONTO, ONTARIO–(March 11, 2016) - Supreme Pharmaceuticals Inc. (the “Company” or “Supreme”) (OTC PINK:SPRWF)(CSE:SL) is pleased to announce its wholly-owned subsidiary, Advanced Medical Marihuana Canada (“AMMCan“) has been granted a license to cultivate medical marijuana pursuant to the Marihuana for Medical Purposes Regulations (the “MMPR“).

About Supreme

Supreme is a Canadian publically traded company committed to becoming a leading supplier of affordable medical cannabis through its wholly-owned subsidiary AMMCan. AMMCan is a federally licensed producer of medical marijuana pursuant to the MMPR operating a 7 Acre hybrid greenhouse facility. The Hybrid Greenhouse combines the best technology of indoor production with the efficiencies and sustainability of a greenhouse, in a single large-format production footprint. Please visit www.supreme.ca and www.ammcan.com for more information.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These risks and uncertainties include, but are not limited to, the Company’s ability to satisfy the conditions associated with its cultivation license, the Company’s ability to obtain a sales license and the related timing considerations, the availability of further financing, consumer interest in its products, competition, regulation, operational and technological risks, and anticipated and unanticipated costs and delays. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995.

Investor Relations
(416) 630-7272
info@supreme.ca
www.supreme.ca

Supreme Completes Pre-License Inspection

Posted by AGORACOM-JC at 8:30 AM on Thursday, December 10th, 2015

  • Announced on December 9, 2015, Health Canada conducted the Pre-License Inspection of Supreme’s hybrid greenhouse facility in Kincardine Ontario

TORONTO, ONTARIO–(Dec. 10, 2015) - Supreme Pharmaceuticals Inc. (the “Company” or “Supreme”) (OTC PINK:SPRWF)(CSE:SL) is pleased to announce on December 9, 2015, Health Canada conducted the Pre-License Inspection of Supreme’s hybrid greenhouse facility in Kincardine Ontario.

About Supreme

Supreme is a Canadian publically traded company committed to becoming a leading supplier of affordable medical cannabis achieved by applying commercial agriculture practices to medical cannabis production. Supreme’s flagship facility is a 342,000 sq. ft. hybrid greenhouse located in Kincardine, Ontario, which has been designed to maximize production efficiencies allowing the Company to pass savings along to its future patients.

FORWARD-LOOKING INFORMATION

This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the timing on competition of the MMPR License conditions for its Southern Ontario facility and the start of production. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and such factors as the Company failing to acquire final MMPR licenses and put the same into production. This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995.

Supreme Pharmaceuticals Inc.
Investor Relations
(416) 630-7272
info@supreme.ca
www.supreme.ca

Supreme Announces Pre-License Inspection Date

Posted by AGORACOM-JC at 4:18 PM on Thursday, December 3rd, 2015

  • Health Canada has scheduled a pre-license inspection of Supreme’s hybrid greenhouse facility in Kincardine, Ontario on December 9, 2015

TORONTO, ONTARIO–(Dec. 3, 2015) - Supreme Pharmaceuticals Inc. (the “Company” or “Supreme”) (OTC PINK:SPRWF)(CSE:SL) is pleased to announce Health Canada has scheduled a pre-license inspection of Supreme’s hybrid greenhouse facility in Kincardine, Ontario on December 9, 2015.

About Supreme

Supreme is a Canadian publically traded company committed to becoming a leading supplier of affordable medical cannabis achieved by applying commercial agriculture practices to medical cannabis production. Supreme’s flagship facility is a 342,000 sq. ft. hybrid greenhouse located in Kincardine, Ontario, which has been designed to maximize production efficiencies allowing the Company to pass savings along to its future patients.””

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the timing on competition of the MMPR License conditions for its Southern Ontario facility and the start of production. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and such factors as the Company failing to acquire final MMPR licenses and put the same into production. This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995.

Supreme Pharmaceuticals Inc.
Investor Relations
(416) 630-7272
info@supreme.ca
www.supreme.ca

Medical marijuana users get OK from province to vaporize anywhere

Posted by AGORACOM-JC at 11:09 AM on Thursday, November 26th, 2015
  • Medical marijuana users in Ontario are now legally able to use vaporizers just about anywhere in the province
  • Liberal government quietly exempted them this week from a law that bans the use of e-cigarettes anywhere regular cigarettes are prohibited. It means medical marijuana users can vaporize in restaurants, at work or on playgrounds

Ronan Levy, with the Canadian Cannabis Clinic, discusses the decision to allow medical marijuana users to smoke virtually anywhere.

Allison Jones, The Canadian Press
Published Wednesday, November 25, 2015 3:30PM EST
Last Updated Wednesday, November 25, 2015 9:01PM EST

 

TORONTO — Medical marijuana users in Ontario are now legally able to use vaporizers just about anywhere in the province.

The Liberal government quietly exempted them this week from a law that bans the use of e-cigarettes anywhere regular cigarettes are prohibited. It means medical marijuana users can vaporize in restaurants, at work or on playgrounds.

Associate Health Minister Dipika Damerla said under the exemption for medical marijuana users, employers or restaurant owners could still ban them from smoking on the premises.

“If it’s bothering somebody, find another place to go and smoke,” she said Wednesday.

“Somebody who really needs it for medical reasons may need to be able to smoke it or vape it. On the other hand, we are very sensitive to people around them. It really is about balancing those rights.”

The exemption is about letting people who are very sick or in a lot of pain to take their prescribed medication when they need to, Damerla said.

Jonathan Zaid, the founder of Canadians for Fair Access to Medical Marijuana, said the new regulations don’t change much since medical marijuana users could already smoke “pretty much” anywhere before the e-cigarette law was passed in May.

“Public places like parks or sidewalks are for sure allowed now in the regulations,” he said.

“So it doesn’t really mean anything new because it has always been allowed. There haven’t been regulations pertaining to vaporizers in the past, but what it does mean is the provincial government is taking a step forward and actually recognizing medical marijuana as a legitimate medicine.”

But Zaid highly doubts the change in regulations will mean medical marijuana users flooding playgrounds and restaurants to vaporize.

“There’s one thing to have a right and there’s another thing to abuse it,” said Zaid, who uses medical marijuana to treat chronic headaches.

“Everyone that I know, including myself, who uses medical cannabis is discreet about it. They just want to use it as their medicine to feel better, to live a better quality of life and they don’t want to be harassed about it, so that also means they’re not typically likely to do it in a very public space.”

Progressive Conservative Leader Patrick Brown said he didn’t want to “make a lot of political hay” over the exemption, but he urged the Liberal government to make sure the new provincial rules are in line with what municipalities have established.

NDP Leader Andrea Horwath didn’t sound especially shocked by the exemption either.

When asked what she would do if someone was smoking marijuana next to her at a restaurant, she laughed and said, “I’ll probably eat more.”

Source: http://www.cp24.com/lifestyle/health/medical-marijuana-users-get-ok-from-province-to-vaporize-anywhere-1.2674237

Supreme Strengthens Management Team with Appointment of New Director

Posted by AGORACOM-JC at 9:35 AM on Thursday, November 19th, 2015

  • Appointment of Navdeep Dhaliwal to the Company’s Board of Directors.
  • Mr. Dhaliwal’s primary focus will be the development of Supreme’s go-to-market strategy in addition to corporate development and capital markets initiatives

TORONTO, ONTARIO–(Nov. 19, 2015) - Supreme Pharmaceuticals Inc. (the “Company” or “Supreme”) (OTC PINK:SPRWF)(CSE:SL) is pleased to announce the appointment of Navdeep Dhaliwal to the Company’s Board of Directors. Mr. Dhaliwal’s primary focus will be the development of Supreme’s go-to-market strategy in addition to corporate development and capital markets initiatives. “This is an exciting time for Supreme. I am looking forward to working with Supreme’s leadership team to leverage my experiences growing businesses, particularly in the online space,” said Mr. Dhaliwal.

Mr. Dhaliwal is a Chartered Accountant and currently serves as the principal of NLX Capital Corp., a Toronto-based corporate development firm focused primarily on technology and renewable energy. Mr. Dhaliwal was recently retained by a Toronto software company where he successfully expanded the company’s business into South East Asia, where Mr. Dhaliwal has extensive business experience.

Mr. Dhaliwal has been involved in the Canadian medical marijuana space for two years prior to joining Supreme and states: “I believe there is a strong positive outlook for the Canadian marijuana industry, particularly amongst producers harnessing the power of sunlight to reduce costs and improve sustainability.”

Concurrent with Mr. Dhaliwal’s appointment, the Supreme’s Board of Directors accepted the resignation of Allan Levien, a long serving director of the Company. Supreme thanks Mr. Levien for his years of dedicated service and wishes him the best in all of his present and future endeavours. Supreme’s President, John Fowler commented: “Mr. Levien was instrumental in transitioning Supreme into the cannabis industry and I am thankful for his vision. I am also very excited to welcome Mr. Dhaliwal to Supreme’s Board of Directors, as he will play an integral role for us as we plan to hit the ground running in the next phase of our business development.”

About Supreme

Supreme is a Canadian publically traded company committed to becoming a leading supplier of affordable medical cannabis achieved by applying commercial agriculture practices to medical cannabis production. Supreme’s flagship facility is a 342,000 sq. ft. hybrid greenhouse located in Kincardine, Ontario, which has been designed to maximize production efficiencies allowing the Company to pass savings along to its future patients.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the timing on competition of the MMPR License conditions for its Southern Ontario facility and the start of production. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and such factors as the Company failing to acquire final MMPR licenses and put the same into production. This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995.

Supreme Pharmaceuticals Inc.
Investor Relations
(416) 630-7272
info@supreme.ca
www.supreme.ca

Medical marijuana includes cookies, brownies, oils and tea rules Supreme Court

Posted by AGORACOM-JC at 11:33 AM on Thursday, June 11th, 2015

The Supreme Court of Canada has ruled that limiting medical consumption to dried marijuana infringes on liberty protections under the Charter of Rights.Cannabis-infused peanut butter cookies are displayed for sale at a Weeds Glass and Gifts medical marijuana dispensary in downtown Vancouver, B.C.

DARRYL DYCK / THE CANADIAN PRESS

Cannabis-infused peanut butter cookies are displayed for sale at a Weeds Glass and Gifts medical marijuana dispensary in downtown Vancouver, B.C.

By: The Canadian Press, Published on Thu Jun 11 2015

OTTAWA—The Supreme Court of Canada says medical marijuana can include products other than dried pot, such as cannabis-infused cookies brownies, oils and tea.

The court has rejected an appeal by the federal government of a lower court ruling that medical marijuana users have a right to a range of products containing the drug.

In a 7-0 decision, the court ruled that limiting medical consumption to dried marijuana infringes on liberty protections under the Charter of Rights.

Current federal regulations stipulate that authorized users of physician-prescribed cannabis can only consume dried marijuana.

The case stems from the arrest in 2009 of Owen Smith, former head baker for the Cannabis Buyers Club of Canada, who was charged after police found more than 200 pot cookies and cannabis-infused olive oil and grapeseed oil in his Victoria apartment.

Medical marijuana registry in Quebec called world’s 1st

Posted by AGORACOM-JC at 10:50 AM on Tuesday, May 12th, 2015
The varying levels of THC in medical marijuana could help to shed light on how safe and effective the drug is for different clinical conditions.
The varying levels of THC in medical marijuana could help to shed light on how safe and effective the drug is for different clinical conditions. (Jeff Chiu/Associated Press)

Medical marijuana users in Quebec can now help shed light on the drug’s long-term safety and effectiveness through a new registry at McGill University in Montreal.

McGill said its medical marijuana registry, which launched on Monday, is the first research database of its kind in the world.

The registry meets a requirement of Quebec’s college of physicians, which considers cannabis an experimental therapy. Under provincial regulation, cannabis can only be prescribed as part of a formal study.

Health Canada estimates over 40,000 Canadians legally consume cannabis to relieve symptoms from diseases including multiple sclerosis, HIV, cancer or epilepsy.

While cannabis has been studied for years as a recreational substance, little is known about its medical use, said Dr. Mark Ware, director of clinical research at McGill’s pain management unit.

“I got frankly tired of giving talks and presentations about the potential medical use of cannabis and always having questions for which I did not have answers,” said Ware. “I hope this study is a step in the direction of trying to fill some of these huge knowledge gaps.”

The registry allows doctors and users of medical marijuana to look for any possible safety concerns.

It will also allow researchers to look for clues about what variations of medical marijuana might work best for which conditions.

Combining information on the patients and the drugs could not only identify potential safety considerations but also start to answer questions about the effectiveness of cannabis under certain clinical conditions, Ware added.

Despite expanding access to medical marijuana globally, the university calls the project a world first. Ware said to his knowledge no country or region has set up such a prospective, formally approved clinical project.

The researchers hope to engage doctors on the front lines to participate in the research — an approach that could be adapted to study the safety and effectiveness of other drugs over the long term.

The data collected will not have any identifiable patient information to protect patient privacy.

The registry will remain active for at least 10 years and involve thousands of patients. Ware hopes to share the data with other provinces and potentially other countries.

Source: http://www.cbc.ca/news/health/medical-marijuana-registry-in-quebec-called-world-s-1st-1.3069316

Puerto Rico governor signs order to legalize medical pot

Posted by AGORACOM-JC at 11:45 AM on Monday, May 4th, 2015
Puerto Rico Gov. Alejandro Garcia Padilla delivers his budget address for the next fiscal year at the Capitol building in San Juan, Thursday, April 30, 2015. Legislators struck down a key part of a plan to overhaul the island's tax system early Thursday, raising concerns about the U.S. territory's economic future and its ability to pay off a heavy public debt. (AP Photo/Ricardo Arduengo)
Puerto Rico Gov. Alejandro Garcia Padilla delivers his budget address for the next fiscal year at the Capitol building in San Juan, Thursday, April 30, 2015. Legislators struck down a key part of a plan to overhaul the island’s tax system early Thursday, raising concerns about the U.S. territory’s economic future and its ability to pay off a heavy public debt. (AP Photo/Ricardo Arduengo)

 

SAN JUAN, Puerto Rico (AP) — Puerto Rico’s governor on Sunday signed an executive order to authorize the use of medical marijuana in the U.S. territory in an unexpected move following a lengthy public debate.

Gov. Alejandro Garcia Padilla said the island’s health secretary has three months to issue a report detailing how the executive order will be implemented, the impact it will have and what future steps could be taken. The order went into immediate effect.

“We’re taking a significant step in the area of health that is fundamental to our development and quality of life,” Garcia said in a statement. “I am sure that many patients will receive appropriate treatment that will offer them new hope.”

The order directs the health department to authorize the use of some or all controlled substances or derivatives of the cannabis plant for medical use.

Garcia said the government also will soon outline the specific authorized uses of marijuana and its derivatives for medical purposes. He noted that medical marijuana is used in the U.S. mainland and elsewhere to treat pain associated with migraines and illnesses including epilepsy, multiple sclerosis and AIDS.

Medical marijuana is already legal in 23 U.S. states, and a group of U.S. legislators is seeking to remove federal prohibitions on it. Elsewhere in the Caribbean, Jamaica recently passed a law that partially decriminalized small amounts of pot and paved the way for a lawful medical marijuana sector.

Jaime Perello, president of Puerto Rico’s House of Representatives, said he supported Garcia’s order.

“It’s a step in the right direction,” he said. “One of the benefits that patients say they receive the most is pain relief.”

Opposition legislator Jenniffer Gonzalez said Garcia’s actions leave the law of controlled substances in what she called a “judicial limbo.”

Back in 2013, Puerto Rico legislators debated a bill that would allow people to use marijuana for medicinal purposes, but a final vote was never taken.

Amado Martinez, an activist who supports legalizing marijuana for all uses, said in a phone interview that he was very surprised by the governor’s actions.

He wondered what type of illnesses would receive authorization for medical marijuana, and whether the medical marijuana will be imported or if people can obtain licenses to grow it on the island.

“There are so many questions. We have to look at all those details,” he said.

Source: http://news.yahoo.com/puerto-rico-governor-signs-order-legalizing-medical-pot-234503470.html

Clinical trials high on list for medical marijuana community

Posted by AGORACOM-JC at 2:42 PM on Tuesday, February 17th, 2015

The medical marijuana movement is asking the scientific community to make examining the therapeutic potential of cannabis in much more depth a priority, cannabis experts from North America and the UK declared on 14 February at the American Association for the Advancement of Science (AAAS) annual meeting in California. But the drug’s controlled status is continuing to slow efforts to investigate the myriad compounds in the plant.

The panellists said the evidence is clear that cannabinoids can treat different types of pain effectively. In addition, they cited some evidence that cannabinoids help with neurological conditions like epilepsy. There is also very early clinical trial data suggesting that the molecule cannabidiol (CBD) has an antipsychotic effect and some evidence that it could help with anxiety disorders.

Although cannabis use is associated with things like short-term memory loss and learning problems, the experts presented data showing that once use is stopped those effects disappear within a few days. They also said there is no proof of any long-term neurocognitive effects of chronic marijuana use on the adult brain, although there is some cause for concern about heavy use by adolescents.

The question of whether the compounds have untoward effects remains unclear due to insufficient research. The field is stalled because large clinical trials require the deep pockets of the pharmaceutical sector, but a major barrier is the lack of intellectual property around some of these compounds. ‘They are old drugs, they are hard to lock in patents, and that makes it difficult for someone to invest significantly into these kinds of research studies that might not have the long-term payback,’ explained Mark Ware, who runs the pain research unit at McGill University, Canada.

However, possession of cannabis is still illegal in most US states making it a difficult drug to work with in the clinic. Igor Grant, a neuropsychiatrist who directs the cannabis research centre at the University of California, San Diego, US, has conducted seven clinical trials that involved smoked or inhaled cannabis and all required that he obtain regulatory approvals from three separate agencies before he could even acquire the cannabis for the studies.

Research marijuana for the US is grown by University of Mississippi under government licence. Once investigators clear all of the approvals, they can request the study drug from the NIH in the form of cigarettes containing different concentrations of tetrahydrocannabinol or THC – the main psychoactive constituent of cannabis.

Cannabis in Canada

Cannabis research is far easier to pursue in Canada where there is a regulated government programme. The country controls cannabis differently to other drugs, arguing that it fits neither under natural health product regulations that govern the use of herbal medicines, nor under the pharmaceutical drug regulations.

Some of the Canadian companies that grow cannabis under licence are now funding clinical trials to try and develop a drug, according to Ware. ‘The money is out there, but the trick is to get these kinds of pilot studies – proof-of-concept studies – done that encourage people to do larger-scale trials,’ he said.

The experts agreed that more information is needed about therapeutic use of cannabis. To help fill this gap, the provincial ethics committee in Quebec recently directed that all patients cleared to use cannabis for medical reasons must agree to be part on an ongoing study. Ware has been tapped to help set up a Quebec-wide registry that will allow these patients to be tracked anonymously for adverse events, as well as for things like pain, spasticity, appetite level and mood. The registry is expected to go live by the end of March.

In the US, there has been much media and public interest in a strain of medical marijuana first developed to treat a child suffering from repeated seizures, dubbed Charlotte’s Web, which is high in CBD but does not contain any psychoactive compounds. But Ware is troubled by the phenomenon of parents and patients seeking out CBD therapeutics. ‘We don’t know where the cannabidiol is coming from; there is a tremendous kind of mythology about the stuff coming from eastern Europe or China,’ he said. Hemp farmers in Canada are being approached to produce CBD and are charging huge amounts of money, he added.

The development of such medicinal products is complicated by the fact that cannabis contains over 100 different ingredients that may be bioactive. This flies in the face of the model followed by regulatory agencies like the US Food and Drug Administration that are set up to deal with single molecules rather than complex mixtures.

Source: http://www.rsc.org/chemistryworld/2015/02/clinical-trials-high-list-medical-marijuana-community

Supreme Completes Operational Transition to Ontario

Posted by AGORACOM-JC at 12:25 PM on Monday, February 9th, 2015

TORONTO, ONTARIO–(Feb. 9, 2015) – Supreme Pharmaceuticals Inc. (the “Company”) (OTC PINK:SPRWF)(CSE:SL) is pleased to announce it has completed its operational transition from British Columbia to Ontario in order to focus resources on the Kincardine facility. The transition allows the Company to reduce operating overhead and focus efforts on obtaining required regulatory approvals at the Kincardine facility.

Further to the transition, Brayden Sutton will be resigning as Executive Vice-President, effective immediately, but will continue on with Company as a consultant for the near term to assist in completing the Company’s operational transition.

John Fowler, President of the Company stated, “Re-focusing our attention on Ontario is a big step in our journey to become a leading supplier of affordable medical marijuana in Canada. It allows us to concentrate on building our business around our flagship greenhouse facility. With our focus set squarely on Kincardine, I feel we are well positioned for future success.”

Currently, the Company continues to prepare for its post-license operations by engaging with various health care providers, patient groups and wholesale partners. At present, no date has been set for the pre-license regulatory inspection.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the timing on competition of the MMPR License conditions for its Southern Ontario facility and the start of production. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and such factors as the Company failing to acquire final MMPR licenses and put the same into production. This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995.

Supreme Pharmaceuticals Inc.
Investor Relations
(604) 674-2191
info@supreme.ca
www.supreme.ca

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks